ADCC Bioassay Effector Cell V Variant (High Affinity)/ NFAT Luciferase Reporter Jurkat Cell Line
ADCC Bioassay Effector Cell V Variant (High Affinity)/NFAT Luciferase Reporter Jurkat Cell Line is an engineered Jurkat T cell line expressing firefly luciferase under the control of NFAT response elements, and human FcγRIIIa high affinity (V158) variant and Fcγ chain. This cell line was functionally validated by ADCC (antibody-dependent cell-mediated cytotoxicity) assays.
Figure 1: Illustration of the mechanism of action of ADCC Bioassay Effector Cell V Variant (High Affinity)/NFAT Luciferase Reporter Jurkat Cell Line.
ADCC Bioassay Effector Cell V Variant (High Affinity)/NFAT Luciferase Reporter Jurkat cells are used as effector cells. The effector cells are co-cultured in the presence of target cells and an antibody of interest. The antibody binds to the target antigen on the target cell whereas its Fc portion binds to FcγRIIIa on the cell surface of the effector cell, cross-linking the effector and target cells. Engagement of FcγRIIIa leads to the activation of the NFAT pathway in the effector cells. Luciferase activity is proportional to the activation of the ADCC cascade.
Interested in screening and profiling inhibitors, blocking antibodies, or activators of FcγRIIIa high affinity (V158) variant without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
This product has been cited 5 times.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2A | BPS Bioscience #60190 |
Materials Required for Cellular Assays
Name | Ordering Information |
Trastuzumab (anti-HER2) Antibody | SelleckChem #A2007 |
Rituximab (anti-CD20) Antibody | SelleckChem #A2009 |
SK-BR-3 Cells | ATCC #HTB-30 |
Human B Cells WIL2-S | ATCC #CRL-8885 |
96-well tissue culture-treated white clear-bottom assay plate | |
One-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune defense mechanism that involves an effector cell lysing a target cell on which antibodies have bound to specific antigens. The typical ADCC involves activation of natural killer (NK) cells by engaged antibodies. NK cells express Fc receptors, mostly FcγRIIIa (CD16a), on their surface. These Fc receptors recognize and bind the Fc portion of an antibody, such as IgG, when the IgG is bound to the surface of a pathogen-infected target cell. Once the Fc receptor binds to the Fc region of IgG, the NK cell releases cytokines such as IFN-γ and cytotoxic molecules that attack the pathogen-infected target cell. Human FcγRIIIa displays a dimorphism at residue 158. F FcγRIIIa V158 encodes a higher affinity receptor variant with a valine at amino acid residue 158, while F158 encodes a lower affinity receptor variant with a phenylalanine at amino acid residue 158.
Cao X., et al., 2022. Science Advances 8 (11): DOI: 10.1126/sciadv.abl9171